EMERGENT BIOSOLUTIONS INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
EMERGENT BIOSOLUTIONS INC. (EBS) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2020-02-25
- EMERGENT BIOSOLUTIONS INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2018-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2018-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2018-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2017-09-30 was 8.10M shares, a 0.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2019 was 0.00 shares.
- EMERGENT BIOSOLUTIONS INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2018 was 0.00 shares, a 100.00% decline from fiscal 2017.
- EMERGENT BIOSOLUTIONS INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2017 was 7.40M shares, a 8.64% decline from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2016 was 8.10M shares, a 4.92% increase from fiscal 2015.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2019-12-31 | 0.00 shares 10-K · filed 2020-02-25 | |||||
| 2018-12-31 | 0.00 shares 10-K · filed 2020-02-25 | |||||
| 2018-09-30 | 0.00 shares 10-Q · filed 2018-11-02 | 0.00 shares 10-Q · filed 2018-11-02 | ||||
| 2018-06-30 | 0.00 shares 10-Q · filed 2018-08-03 | 0.00 shares 10-Q · filed 2018-08-03 | ||||
| 2018-03-31 | 0.00 shares 10-Q · filed 2018-05-04 | |||||
| 2017-12-31 | 7.40M shares 10-K · filed 2020-02-25 | 7.40M shares 10-K · filed 2018-02-23 | ||||
| 2017-09-30 | 8.10M shares 10-Q · filed 2018-11-02 | 8.10M shares 10-Q · filed 2018-11-02 | ||||
| 2017-06-30 | 8.10M shares 10-Q · filed 2018-08-03 | 8.10M shares 10-Q · filed 2018-08-03 | ||||
| 2017-03-31 | 8.10M shares 10-Q · filed 2018-05-04 | |||||
| 2016-12-31 | 8.10M shares 10-K · filed 2019-02-22 | 8.10M shares 10-K · filed 2017-02-28 | ||||
| 2016-09-30 | 8.10M shares 10-Q · filed 2017-11-03 | 8.10M shares 10-Q · filed 2017-11-03 | ||||
| 2016-06-30 | 0.00 shares 10-Q · filed 2017-08-04 | 7.72M shares 10-Q · filed 2017-08-04 | 0.00 shares 10-Q · filed 2016-08-05 | |||
| 2016-03-31 | 7.72M shares 10-Q · filed 2017-05-05 | |||||
| 2015-12-31 | 7.72M shares 10-K · filed 2018-02-23 | |||||
| 2015-09-30 | 7.72M shares 10-Q · filed 2016-11-09 | 7.72M shares 10-Q · filed 2016-11-09 | ||||
| 2015-06-30 | 7.72M shares 10-Q · filed 2016-08-05 | 0.00 shares 10-Q · filed 2016-08-05 | ||||
| 2015-03-31 | 0.00 shares 10-Q · filed 2016-05-06 | |||||
| 2014-12-31 | 7.72M shares 10-K · filed 2017-02-28 | |||||
| 2014-09-30 | 8.10M shares 10-Q · filed 2015-11-06 | 0.00 shares 10-Q · filed 2015-11-06 | ||||
| 2014-06-30 | 0.00 shares 10-Q · filed 2015-08-06 | 0.00 shares 10-Q · filed 2015-08-06 | ||||
| 2014-03-31 | 0.00 shares 10-Q · filed 2015-05-08 | |||||
| 2013-12-31 | 0.00 shares 10-K · filed 2016-02-29 | |||||
| 2013-09-30 | 0.00 shares 10-Q · filed 2014-11-10 | 0.00 shares 10-Q · filed 2014-11-10 | ||||
| 2013-06-30 | 0.00 shares 10-Q · filed 2014-08-08 | 0.00 shares 10-Q · filed 2014-08-08 | ||||
| 2012-12-31 | 0.00 shares 10-K · filed 2015-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |